For patients newly diagnosed with small cell lung cancer (SCLC), the conversation about clinical trials should begin immediately, not after other treatments have failed. That’s the message from Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, and patient advocate Wendy Brooks, who is living with SCLC. Their discussion, featured on the Hope With Answers podcast, highlights a critical shift in how clinical trials are positioned in the treatment journey.
SCLC is an aggressive cancer that often leaves little time for deliberation. Yet many patients and families may not realize that some clinical trials are only available before any treatment starts, while others are testing promising new therapies as a first-line option. “There are a lot of changes going on in the landscape today, more than we've seen for a very long time,” Saxena says. “Emerging treatments now involve immunotherapy, where your immune system attacks small cell lung cancer. Studies are also exploring antibody-drug conjugates, antibodies that target specific proteins in small cell cancer and deliver chemotherapy with them, rather than free-flowing chemotherapy in your bloodstream.” These innovations, along with a deeper understanding of SCLC biology, could lead to more personalized care and better outcomes.
The implications for patients are profound. For decades, treatment options for SCLC were limited, and survival rates remained stubbornly low. Now, clinical trials are not only testing new drugs but also redefining what success looks like. Researchers are increasingly tracking patient-reported outcomes—such as fatigue, breathing difficulties, pain, and emotional well-being—alongside traditional measures like tumor shrinkage. “The goal is to have meaningful time, not just more time,” Saxena emphasizes. This focus on quality of life means that even if a treatment isn’t curative, it may still offer valuable periods of improved daily functioning and reduced symptoms.
Patients themselves play a vital role in this process. Brooks, a member of the Lung Cancer Foundation of America’s Voices of Hope Speakers Bureau, encourages others to speak up about side effects and changes in how they feel. That feedback helps doctors adjust dosages and manage symptoms, potentially allowing patients to stay on treatment longer. In clinical trials, it also gives researchers real-world data on how therapies affect daily life. “I'm more hopeful today than I have ever been,” Brooks says.
The urgency of asking about clinical trials early cannot be overstated. For a fast-moving cancer like SCLC, waiting could mean missing an opportunity. As Saxena and Brooks make clear, the question “Is there a clinical trial that might be right for me?” should be asked at the first appointment and revisited throughout treatment. It’s a simple question that could open doors to cutting-edge therapies and, just as importantly, to a better quality of life. To learn more, visit LCFAmerica.org.
